Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HBM Holdings Ltd. ( (HK:2142) ) has shared an announcement.
HBM Holdings has reported promising preclinical results for LET003, its first AI-enabled, next-generation ACVR2A/2B-targeting monoclonal antibody for obesity treatment, developed on the Hu-mAtrIx platform. In animal models, LET003 showed superior pharmacokinetic properties to rival molecules, suggesting it could achieve similar efficacy at lower doses or with longer dosing intervals, which may enhance its competitiveness against existing therapies.
When combined with semaglutide in obesity models, LET003 significantly boosted fat reduction while mitigating lean mass loss, improving both absolute fat loss and lean mass preservation versus semaglutide alone. Additional studies in high-fat diet and normal diet models showed that LET003 improved body composition and promoted lean mass more effectively than comparator antibodies, underscoring its potential as a best-in-class obesity therapy and strengthening HBM’s positioning in the rapidly evolving obesity treatment landscape.
The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
More about HBM Holdings Ltd.
HBM Holdings Limited is a biotechnology company focused on developing innovative antibody-based therapies using its Hu-mAtrIx platform. The group targets major chronic conditions, with a growing emphasis on obesity and metabolic diseases, positioning itself in the competitive global biopharmaceutical and obesity-treatment markets.
Average Trading Volume: 3,429,966
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.38B
See more data about 2142 stock on TipRanks’ Stock Analysis page.